GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00909051

Enrollment

15729

Registered

2009-05-27

Start date

2009-03-24

Completion date

2010-12-31

Last updated

2023-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

Diabetes Mellitus

Brief summary

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

Interventions

DRUGAcarbose (Glucobay, BAYG5421)

Patients with diabetes type 2 newly treated with Glucobay

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Data collection on patients weight and waist circumference, fasting blood glucose, postprandial blood glucose (2h), HbA1C; exploratory analysis according to patient groups (concomitant cardiovascular disease groups, BMI)	During observation period of three months

Countries

Algeria, Bosnia and Herzegovina, Cambodia, China, Hong Kong, India, Indonesia, Malaysia, Moldova, Pakistan, Philippines, Russia, Singapore, South Korea, Thailand, Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026